The top three resistant drugs associated with high TMED2 expression were Zibotentan, GSK429286A, and Temozolomide, according to the GDSC (Genomics of Drug Sensitivity in Cancer) dataset (Figure 7B). The gene discussed is TMED2; the disease is cancer.